Last Price
274.91
Today's Change
+0.34 (0.12%)
Day's Change
271.75 - 276.07
Trading Volume
453,982
Market Cap
35 Billion
Shares Outstanding
128 Million
Avg Volume
928,590
Avg Price (50 Days)
261.74
Avg Price (200 Days)
194.16
PE Ratio
-499.84
EPS
-0.55
Earnings Announcement
31-Oct-2024
Previous Close
274.57
Open
275.50
Day's Range
271.75 - 276.07
Year Range
141.98 - 287.55
Trading Volume
453,982
1 Day Change
0.12%
5 Day Change
-0.11%
1 Month Change
-2.06%
3 Month Change
13.13%
6 Month Change
83.95%
Ytd Change
41.03%
1 Year Change
57.97%
3 Year Change
55.25%
5 Year Change
241.84%
10 Year Change
249.76%
Max Change
4474.21%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.